Gregory W Charville

Associate Professor

Stanford University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (28)

Case: An 18-year-old man with no significant medical history presented with persistent anterior knee pain. Imaging revealed multifocal marrow-replacing lesions in the distal femur and patella. Open biopsy confirmed the diagnosis of pseudomyogenic hemangioendothelioma. Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography showed intense multifocal hypermetabolism (SUVmax 13.8). Surgery was deferred due to morbidity, so the patient was treated with intravenous zoledronic acid, resulting in clinical improvement and sustained radiographic and metabolic response over 18 months (SUVmax reduced to 2.26). Conclusion: This case highlights a durable radiographic and clinical response to zoledronic acid monotherapy in multifocal pseudomyogenic hemangioendothelioma, supporting its role as a function-preserving systemic therapy.

Year:

2025

Shows biophysical and biochemical assays, including SPR, GST pulldown, streptavidin pulldown, and TR-FRET, demonstrating compound-induced interactions between TRIM21 and NUP98, and a schematic of the molecular glue mechanism.

Year:

2025

Cancer cells are acutely dependent on nuclear transport due to elevated transcriptional activity, suggesting an unrealized opportunity for selective therapeutic inhibition of the nuclear pore complex (NPC). Through large-scale phenotypic profiling of cancer cell lines, genome-scale functional genomic modifier screens, and mass spectrometry–based proteomics, we discovered that the clinical drug PRLX-93936 is a molecular glue that binds and reprograms the TRIM21 ubiquitin ligase to degrade the NPC. Upon compound-induced TRIM21 recruitment, the nuclear pore is ubiquitylated and degraded, resulting in the loss of short-lived cytoplasmic mRNA transcripts and the induction of cancer cell apoptosis. Direct compound binding to TRIM21 was confirmed via surface plasmon resonance and X-ray crystallography, whereas compound-induced TRIM21–nucleoporin complex formation was demonstrated through multiple orthogonal approaches in cells and in vitro . Phenotype-guided optimization yielded compounds with 10-fold greater potency and drug-like properties, along with robust pharmacokinetics and efficacy against pancreatic cancer xenografts and patient-derived organoids. Significance: This study establishes the cancer therapeutic potential of optimized TRIM21 molecular glues to degrade the NPC and underscores the value of reexamining drugs with previously unknown mechanisms using current technologies.

Year:

2025

Shows proteomic and imaging analyses demonstrating TRIM21-dependent rapid degradation of nuclear pore complex proteins by PRLX and JWZ-8-103, including LC-MS/MS profiling, structural mapping, and confocal microscopy.

Year:

2025

Presents pharmacokinetic analyses and in vivo efficacy of TRIM21-targeting compounds in organoid and xenograft models, including immunoblotting, plasma concentration profiles, and tumor growth studies.

Year:

2025

Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.

Year:

2025

Insulinoma-associated protein 1 (INSM1) is a relatively new immunostain used in the diagnostic assessment of tumors with neuroendocrine differentiation. While INSM1 positivity has been described in some non-neuroendocrine neoplasms, reactivity in red blood cells (RBCs) has only been anecdotally noted in one prior study without description of the degree/extent of staining. INSM1 staining in nucleated erythroid precursors has not been previously reported. Herein, 100 small biopsy specimens containing RBCs where INSM1 was used for diagnostic workup were reviewed. Additionally, 5 benign bone specimens and 5 adrenal myelolipoma specimens containing nucleated erythroid precursors were stained with INSM1. INSM1 staining intensity (0–3) and staining extent (0–100%) in RBC/erythroid cells was evaluated and an H-score was calculated (0–300). Positive cytoplasmic INSM1 staining in RBCs was observed in 99/100 (99%) specimens, with mean staining intensity of 2.1 (median = 2) and mean staining percent of 59% (median = 70%), with mean H-score of 125 (median = 140). Positive cytoplasmic INSM1 staining was identified in 10/10 (100%) specimens containing nucleated erythroid precursors, with mean staining intensity of 2.7 (median = 3) and mean staining percent of 53% (median = 50%), with mean H-score of 132 (median = 120). INSM1 is frequently positive in RBCs and nucleated erythroid precursors, albeit with variable staining intensity and extent. Although the INSM1 staining is cytoplasmic in RBCs (lacking nuclei) and nucleated erythroid precursors, the morphological features can mimic positive nuclear staining of neuroendocrine neoplasms. Particularly in small biopsy samples, which often contain background RBCs, positive INSM1 staining should be reviewed with caution to avoid misdiagnosis of neuroendocrine differentiation.

Year:

2025

Supplementary Table 14. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 2 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).

Year:

2025

Supplementary Table 13. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 1 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).

Year:

2025

Supplementary Table 10. Summary of selected clinicopathological features of patient cohorts in the present study (De Bellis et al.) and in the previous studies published by Salas et al. and Kohsaka et al.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (29)

Timothy Sears

University of California, San Diego

UNITED STATES
View details

Wenzhi Ji

Post/staff Scientist

Stanford University

UNITED STATES
View details

Benjamin Haibe-Kains

University of Toronto

CANADA
View details

Matt van de Rijn

prof

Stanford University

UNITED STATES
View details

Garry Nolan

Professor and Carlota A. Harris Professor

Stanford University School of Medicine

UNITED STATES
View details

Aaron Newman

Associate Professor

Stanford University

UNITED STATES
View details

Guolan Lu

Assistant Professor

Stanford University

UNITED STATES
View details

Ulrike Peters

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Everett J. Moding

Stanford University

UNITED STATES
View details

Cooper Rutland

Clinical Assistant Professor

University of Michigan

UNITED STATES
View details

James Zou

Stanford University

UNITED STATES
View details

Stephen Hinshaw

Stanford University

UNITED STATES
View details

Robert B. West

Stanford University School of Medicine

UNITED STATES
View details

Zhenqin Wu

Assistant Professor

The University of Hong Kong

HONG KONG
View details

Scott Dixon

Associate Professor

Stanford University

UNITED STATES
View details

Hans-Christoph Becker

Professor

Stanford University School of Medicine

UNITED STATES
View details

Ankur R. Sangoi

Stanford University

UNITED STATES
View details

Marta Lohman, DVM

Stanford University

UNITED STATES
View details

Deana Colburg

Stanford University

UNITED STATES
View details

Justin M M Cates

Professor

Wake Forest Baptist Medical Center

UNITED STATES
View details

Kristen N. Ganjoo

Stanford University School of Medicine

UNITED STATES
View details

Calvin Kuo

Professor

Stanford University

UNITED STATES
View details

Steven Corsello

Stanford University

UNITED STATES
View details

John Hickey

Assistant Professor

Duke University

UNITED STATES
View details

Nathanael S. Gray

Stanford University

UNITED STATES
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Jeanne Shen

Associate Professor

Stanford University

UNITED STATES
View details

Jennifer Roth

Broad Institute

UNITED STATES
View details

Kyle Loh

Associate Professor and The Anthony DiGenova Endowed Faculty Scholar

Stanford University School of Medicine

UNITED STATES
View details